Moderna jumps 11% as it starts COVID-19 vaccine trial

Monday, 27. July 2020 13:02

Moderna shares jumped over 11% in premarket trade on Monday as the company announced the beginning of its mRNA COVID-19 vaccine Phase 3 COVE study which will include around 30,000 people in the United States.

Additionally, the biotech company said that it is on track to deliver some 500 million doses of the COVID-19 vaccine annually. Moderna stressed the number could even increase to 1 billion doses per year as a result of its cooperation with Lonza.

Moderna stocks surged 11.32% at 7:01 am ET.

Related Links: 
Breaking the News / VP